<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273154</url>
  </required_header>
  <id_info>
    <org_study_id>BUS-IV-01</org_study_id>
    <nct_id>NCT02273154</nct_id>
  </id_info>
  <brief_title>Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Si Tianmei</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multicenter, open lable, parallel randomized controlled clinical trial.

      This study aimed to evaluate the treatment onset time, efficacy and safety in patients with
      major depressive disorders , accompanying anxiety receiving Buspirone and Paroxetine.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of onset of effect</measure>
    <time_frame>8 weeks</time_frame>
    <description>defined as ≥20% change in HAMD total scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical response rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>defined as ≥50% change in HAMD total scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>remission rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Defined as HAMD total score ≤10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of HAMD scores at week 4 and week 8 compared with baseline</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of HAMA scores at week 4 and week 8 compared with baseline</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Major Depression Disorder</condition>
  <arm_group>
    <arm_group_label>paroxetine and buspirone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive paroxetine (20-60mg/d) and buspirone(30mg/d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paroxetine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>receive paroxetine (20-60mg/d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone</intervention_name>
    <description>MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)</description>
    <arm_group_label>paroxetine and buspirone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>MDD patients with anxiety disorder take paroxetine (20-60mg/d)</description>
    <arm_group_label>paroxetine and buspirone group</arm_group_label>
    <arm_group_label>paroxetine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients meeting Statistical Manual of Mental Disorders IV (DSM-IV) criteria for major
             depression disorder , Hamilton Depression Rating Scale(HAM-D) score was 17 or above,
             Hamilton Anxiety Scale（HAMA）score was 7 or above.

          2. aged 18-65 years( including 18,65 years )

          3. male and female and inpatient as well as outpatient.

          4. Written informed consent was obtained from each patient before therapy. -

        Exclusion Criteria:

          1. Patients with pregnant or breast-feeding and not taking effective contraceptive
             measures

          2. Patients were allergic to buspirone or with a known intolerance to contraindication

          3. Patients with clinically severe and unstable disease ,and not suitable to participate
             the study judged by the investigators

          4. Patients with nervous system diseases(such as epilepsy, Brain injury, Multiple
             Sclerosis, Degenerative disease including acute lateral sclerosis, Parkinson's
             disease, ataxy)

          5. Patients with a mental illness according to the DSM-IV, such as Organic mental
             disorders, Schizophrenia, Shizoaffective disorder, delusional disorder,
             Undifferentiated schizophrenia, bipolar disorder, and patients with a history of
             substance abuse including alcohol and active drug within 12 months of screening.

          6. Patients are taking other Psychiatric drugs (such as Antipsychotic drugs,
             Anticonvulsant and Mood stabilizer but not include Antihistamine agents) and receiving
             ECT that might be excluded.

          7. Patients worked on professional drivers or dangerous works

          8. Patients participated in clinical trials within the past 30 days and treated with
             drugs from sponsors are not eligible.

          9. Patients with clinically significant abnormalities on electrocardiogram or laboratory
             tests

         10. Patients with Acute Angle-closure Glaucoma

         11. Patients with Myasthenia Gravis

         12. Patients who have used Monoamine oxidase inhibitors (MAOI) within 2 weeks of Screening

         13. Patients who were Refractory depression invalid or non-responsive to adequate dosage
             (therapeutic dose upper limit) and duration (up 6 weeks) with two or above different
             antidepressants.

         14. Patients who pose a suicidal risk, HAMD suicide score was 3 or above . -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of mental health, Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tianmei Si, PhD.</last_name>
      <phone>8610-82801960</phone>
      <email>si.tian-mei@163.com</email>
    </contact>
    <investigator>
      <last_name>Tianmei Si, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan mental health center</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luxian Lv, MD.</last_name>
      <phone>86-13837320007</phone>
      <email>lvluxian86@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan mental health center</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maosheng Fang, MD.</last_name>
      <phone>86-13553013182</phone>
      <email>fangmaosheng@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Brain Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhijian Yao, PhD.</last_name>
      <phone>86-13851580276</phone>
      <email>zhijianyao@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalian No.7 People's Hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shoufu Xie, MD.</last_name>
      <phone>86-18441168381</phone>
      <email>shoufuxie@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Dayi Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Yang, MD.</last_name>
      <phone>86-13903414208</phone>
      <email>hongyang1964@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <last_update_submitted>October 22, 2014</last_update_submitted>
  <last_update_submitted_qc>October 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Si Tianmei</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>major depressive disorder</keyword>
  <keyword>Efficacy and safety of buspirone add-one treatment in patients with major depression disorder</keyword>
  <keyword>buspirone</keyword>
  <keyword>paroxetine</keyword>
  <keyword>anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

